Target intelligence / Profile preview

Cytochrome c, somatic (CYCS)

Target
CYCS
Molecular classification
Enzyme (specifically, electron carrier protein in the mitochondrial electron transport chain), Peripheral membrane protein, Cytochrome
01

Overview

Cytochrome c, somatic (CYCS) is a highly conserved, small heme protein located in the mitochondrial intermembrane space, where it is essential for electron transport during cellular respiration[1][2][3][4]. It transfers electrons between Complex III (cytochrome bc1) and Complex IV (cytochrome c oxidase), enabling ATP synthesis[1][2]. Cytochrome c also has a pivotal signaling role in apoptosis; upon mitochondrial membrane permeabilization, it is released into the cytosol, where it binds Apaf-1 and triggers caspase activation, leading to programmed cell death[1][2]. Apart from its canonical roles, cytochrome c may act as an antioxidative enzyme and participate in the cellular response to oxidative stress[1]. Mutations in CYCS have been linked with inherited platelet disorders such as Thrombocytopenia 4[2][3]. While not a direct drug target in approved therapies, its functions and regulations are central to mechanisms of a broad range of diseases, especially those involving defective apoptosis or mitochondrial dysfunction[1][2][4].

Other names
Cytochrome cCYCHCSTHC4
02

Mechanism of action

Agents that cause mitochondrial outer membrane permeabilization promote cytochrome c release, triggering caspase activation and apoptosis[1][2]. Some antioxidants or pro-oxidant therapies may influence cytochrome c-related pathways.

03

Biological functions

Electron transport/respiratory chain in mitochondriaApoptosis (cell death signaling)Reactive oxygen species detoxification
04

Disease associations

CancerNeurodegenerative diseaseThrombocytopenia (Thrombocytopenia 4 and autosomal dominant nonsyndromic thrombocytopenia)Other (implicated in conditions involving defective apoptosis or mitochondrial dysfunction)
05

Safety considerations

Therapeutic modulation of cytochrome c is challenging because global inhibition may disrupt mitochondrial respiration, while excessive activation may cause widespread apoptosis and tissue damage[1].
06

Interacting drugs

No direct FDA-approved drugs target cytochrome c itself, but it is affected indirectly by various experimental pro-apoptotic agents and investigational drugs that modulate mitochondrial pathways. Agents that affect Bcl-2 family proteins, for example, can indirectly trigger cytochrome c release[1][2].
07

Biomarkers

Cytochrome c release into the cytosol or extracellular space is a biomarker of cell apoptosis and an indicator of tissue injury or disease state in research and clinical studies[1].

Beyond the preview

Go deeper on Cytochrome c, somatic (CYCS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome c, somatic (CYCS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call